Reckitt Announces Expiration and Results of Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Company Notes due 2044

SLOUGH, United Kingdom, Aug. 14, 2026 /PRNewswire/ -- Reckitt Benckiser Group plc ("Reckitt") (LSE: RKT) announced today (i) the expiration and results of its wholly-owned subsidiary, Mead Johnson Nutrition Company's ("MJN"), previously announced cash tender offer (the "Tender Offer") to purchase any and all of its outstanding 4.600% Senior Notes due 2044 (CUSIP No. 582839 AG1; ISIN US582839AG14) (the "Notes") and (ii) receipt of consents in connection with MJN's previously announced solicitation of consents (the "Consents") from registered holders (each, a "Holder" and, collectively, the "Holders") of the Notes (the "Consent Solicitation") to proposed amendments to the indenture governing the Notes, as supplemented (the "Indenture"), providing for, among other things, the elimination of substantially all of the restrictive covenants and certain events of default and the release of Reckitt's guarantee of the Notes (the "Proposed Amendments"). The terms and conditions of the Tender Offer and the Consent Solicitation are described in the Offer to Purchase and Consent Solicitation Statement, dated August 5, 2026 (the "Statement").

$400,415,000 aggregate principal amount of Notes were validly tendered and not validly withdrawn prior to 5:00 p.m., New York City time, on August 13, 2026 (the "Expiration Time") pursuant to the Tender Offer and Consents delivered pursuant to the Consent Solicitation. The settlement date for Notes validly tendered and not validly withdrawn prior to the Expiration Time and accepted for purchase by MJN is expected to be August 18, 2026 (the "Settlement Date"). Holders of Notes that were validly tendered and not validly withdrawn prior to the Expiration Time will receive the total consideration of $898.00 per $1,000 principal amount of Notes tendered and accepted for purchase, plus accrued and unpaid interest from the last date on which interest had been paid to, but excluding, the Settlement Date. $99,585,000 in aggregate principal amount of Notes will be outstanding on the Settlement Date after giving effect to the settlement of such tendered Notes.

The Tender Offer and the Consent Solicitation expired at the Expiration Time and no tenders of Notes submitted after the Expiration Time are valid. The Tender Offer and the Consent Solicitation were subject to the satisfaction or waiver of certain General Conditions (as defined in the Statement), all of which were satisfied or waived as of the Expiration Time.

In conjunction with receiving the Requisite Consents (as defined in the Statement), MJN intends to execute a supplemental indenture with respect to the Indenture (the "Supplemental Indenture") to effect the Proposed Amendments. The Supplemental Indenture is expected to become operative on the Settlement Date. Upon becoming operative, the Proposed Amendments will apply to all Holders of the Notes remaining outstanding after the Settlement Date, and Holders may obtain the Supplemental Indenture from Reckitt upon request.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any security. No offer, solicitation, or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. Neither the delivery of the Statement nor any purchase of Notes nor acceptance of Consents shall, under any circumstances, create any implication that there has been no change in MJN or its affiliates' affairs since the date thereof, or that the information included in the Statement or incorporated by reference therein is correct as of any time subsequent to the date thereof, as applicable.

Deutsche Bank Securities Inc. and Merrill Lynch International are the dealer managers in the Tender Offer and the solicitation agents for the Consent Solicitation (each a "Dealer Manager"). Global Bondholder Services Corporation has been retained to serve as the tender and information agent (the "Tender and Information Agent") for the Tender Offer and the Consent Solicitation. Questions regarding the Tender Offer and the Consent Solicitation should be directed to the Dealer Managers at Deutsche Bank Securities Inc., Telephone (Europe): +44 20 7545 8011, Telephone (U.S.): +1 (212) 250-2955 and Telephone (U.S. Toll Free): +1 (866) 627-0391 and Merrill Lynch International, Telephone (Europe): + 44 20 7996 5420, Telephone (U.S. Toll Free): +1 (888) 292-0070 and Telephone (U.S.): +1 (980) 387-3907. Requests for copies of the Statement and other related materials should be directed to the Tender and Information Agent, Telephone (U.S. Toll Free): +1 (855) 654-2015, Telephone (U.S. Collect): +1 (212) 430-3774, Email: [email protected], Website: https://www.gbsc-usa.com/meadjohnson.

About Reckitt and MJN

Reckitt makes the products people trust to care for the ones they love. Reckitt is home to some of the world's best-loved consumer health and hygiene brands, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet. Consumers are at the heart of everything Reckitt does. By creating innovative, science-backed solutions, Reckitt supports people every day to live healthier lives. Reckitt exists to protect, heal and nurture in the pursuit of a cleaner, healthier world. This commitment goes beyond the products it makes. Through its actions, Reckitt expands access to healthcare, education and economic opportunities. Reckitt supports the planet by reducing waste, conserving resources and driving sustainable innovation. Reckitt believes good health starts at home. With every action it takes, Reckitt strives to make its consumers' lives easier, cleaner and healthier, to strengthen communities and to create a more sustainable future. Find out more or get in touch with Reckitt at www.reckitt.com.

*Reckitt is the trading name of the Reckitt Benckiser group of companies

MJN, a wholly owned subsidiary of Reckitt, is a global provider of paediatric nutrition products. Its "Enfa" family of brands includes Enfamil infant formula and other established brands in the sector.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as "anticipate," "estimate," "believe," "continue," "could," "intend," "may," "plan," "potential," "predict," "should," "will," "expect," "objective," "projection," "forecast," "goal," "guidance," "outlook," "effort," "target," "trajectory" or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are based on certain assumptions and analyses made by Reckitt and its subsidiaries, including MJN (together, the "Group") in light of the Group's experience and its perception of historical trends, current conditions and expected future developments, as well as other factors the Group believes are appropriate in the circumstances.

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Factors that might cause or contribute to a material difference include the general economic, business, political, geopolitical and social conditions in the key markets in which the Group operates; the Group's ability to innovate and remain competitive; the Group's investment choices in its portfolio management; the ability of the Group to address existing and emerging environmental and social risks and opportunities; the ability of the Group to manage regulatory, tax and legal matters, including changes thereto; the reliability of the Group's technological infrastructure or that of third parties on which the Group relies including the risk of cyber-attacks; interruptions in the Group's supply chain and disruptions to its production facilities; economic volatility including tariffs, and increases in the cost of labor, raw materials and commodities; the execution of acquisitions, divestitures and business transformation projects; product safety and quality, and the reputation of the Group's global brands; and the recruitment and retention of key management.

All forward-looking statements set forth in this release are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Forward-looking statements set forth in this release speak only as of the date hereof, and we do not undertake any obligation to update forward-looking statements to reflect subsequent events or circumstances, changes in expectations or the occurrence of unanticipated events, except to the extent required by law.

Contact Details
Catheryn O'Rourke
+44 (0) 1753 217 800
General Counsel & Company Secretary

Nick Ashworth
+44 (0) 7408 812350
Investor Relations

SOURCE Reckitt